JP2014533729A - ケルセチンを含有するc型肝炎ウイルスの感染を治療するための医薬品 - Google Patents
ケルセチンを含有するc型肝炎ウイルスの感染を治療するための医薬品 Download PDFInfo
- Publication number
- JP2014533729A JP2014533729A JP2014543531A JP2014543531A JP2014533729A JP 2014533729 A JP2014533729 A JP 2014533729A JP 2014543531 A JP2014543531 A JP 2014543531A JP 2014543531 A JP2014543531 A JP 2014543531A JP 2014533729 A JP2014533729 A JP 2014533729A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- vitamin
- quercetin
- composition comprises
- folic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
Description
大部分のウイルスと同様に、HCVは、感染性のウイルス粒子を複製及び生成するために宿主細胞タンパク質に依存する。宿主細胞タンパク質のなかでは、HCVが増殖するには熱ショックタンパク質(HSP)が必要である。HSPは、分子シャペロンとして知られる細胞内タンパク質である。HSPは、タンパク質の適切なフォールディングに関与するとともに、損傷又はストレスに対する細胞性応答にも関与する。ケルセチンは、ビタミンB3、ビタミンC及び葉酸化合物のうちの一つ以上との併用により、HCVの増殖に必要とされる熱ショックタンパク質の合成を相乗的に阻害する。
本明細書に開示されている特徴の全ては、任意の組み合わせにて組み合わせられ得る。本明細書に開示されている各特徴は、同一の、同等の、或いは類似の目的を果たす代替的な特徴によって置き換えることができる。従って、明示的に別段の定めをした場合を除き、開示された各特徴は、一般的な系列の同等の、或いは類似の特徴のほんの一例である。
Claims (22)
- C型肝炎ウイルス感染を治療するための方法であって、前記方法は、治療を必要とする対象者に、有効量の組成物であって、ケルセチン及び、ビタミンB3、ビタミンC又は葉酸化合物、を含む組成物を投与することを含む、方法。
- 組成物はビタミンB3を含む、請求項1に記載の方法。
- 組成物はビタミンCを含む、請求項1に記載の方法。
- 組成物は葉酸化合物を含む、請求項1に記載の方法。
- 葉酸化合物は、L−メチル葉酸塩である、請求項4に記載の方法。
- 組成物はビタミンCを含む、請求項2に記載の方法。
- 組成物は葉酸化合物を含む、請求項6に記載の方法。
- 葉酸化合物は、L−メチル葉酸塩である、請求項7に記載の方法。
- 組成物は葉酸化合物を含む、請求項2に記載の方法。
- 組成物は葉酸化合物を含む、請求項3に記載の方法。
- 組成物は、ゲニステイン、ゲニスチン、クルクミン、レスベラトロル、ルテオリン、エピガロカテキン没食子酸塩(EGCG)、コエンザイムQ10、エイコサペンタエン酸(EPA)及びドコサヘキサエン酸(DHA)の一つ以上を更に含む、請求項1に記載の方法。
- 組成物は、ルテオリン又はエピガロカテキン没食子酸塩(EGCG)を含む、請求項11に記載の方法。
- 組成物は抗ウイルス薬とともに投与される、請求項1に記載の方法。
- 抗ウイルス薬は、ペグインターフェロンアルファ、リバビリン、ボセプレビル又はテラプレビルである、請求項13に記載の方法。
- 熱ショックタンパク質レベルの上昇に関連した疾患を治療するための方法であって、前記方法は、治療を必要とする対象者に、有効量の組成物であって、ケルセチンと、ビタミンB3、ビタミンC又は葉酸化合物の一つ以上と、を含む組成物を投与することを含む、方法。
- 組成物はビタミンB3を含む、請求項15に記載の方法。
- 組成物はビタミンCを含む、請求項16に記載の方法。
- 組成物は葉酸化合物を含む、請求項17に記載の方法。
- 葉酸化合物は、L−メチル葉酸塩である、請求項18に記載の方法。
- 組成物は、ゲニステイン、ゲニスチン、クルクミン、レスベラトロル、ルテオリン、エピガロカテキン没食子酸塩(EGCG)、コエンザイムQ10、エイコサペンタエン酸(EPA)及びドコサヘキサエン酸(DHA)の一つ以上を更に含む、請求項15に記載の方法。
- 組成物は、ルテオリン又はエピガロカテキン没食子酸塩(EGCG)を含む、請求項20に記載の方法。
- 疾患は、自己免疫疾患、血管疾患、妊娠に関連した疾患、ウイルス感染、又は肝臓もしくはその他のがんである、請求項15に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/303,467 US20130129680A1 (en) | 2011-11-23 | 2011-11-23 | Method for treating hepatitis c virus infection using quercetin-containing compositions |
US13/303,467 | 2011-11-23 | ||
PCT/US2012/066027 WO2013078184A2 (en) | 2011-11-23 | 2012-11-20 | Method for treating hepatitis c virus infection using quercetin-containing compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2014533729A true JP2014533729A (ja) | 2014-12-15 |
Family
ID=48427178
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014543531A Pending JP2014533729A (ja) | 2011-11-23 | 2012-11-20 | ケルセチンを含有するc型肝炎ウイルスの感染を治療するための医薬品 |
Country Status (14)
Country | Link |
---|---|
US (1) | US20130129680A1 (ja) |
EP (1) | EP2782578A4 (ja) |
JP (1) | JP2014533729A (ja) |
KR (1) | KR20140102227A (ja) |
CN (1) | CN104487074A (ja) |
AU (1) | AU2012340840B2 (ja) |
BR (1) | BR112014012610A2 (ja) |
CA (1) | CA2856506A1 (ja) |
HK (1) | HK1208364A1 (ja) |
IN (1) | IN2014MN00999A (ja) |
MX (1) | MX2014006244A (ja) |
RU (1) | RU2014125062A (ja) |
WO (1) | WO2013078184A2 (ja) |
ZA (1) | ZA201404494B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021524495A (ja) * | 2018-07-10 | 2021-09-13 | ヌチド リミテッド | 酸化的ストレスおよびミトコンドリアストレスから,細胞を保護する組成物 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160287533A1 (en) * | 2013-11-27 | 2016-10-06 | Research Foundation Of The City University Of New York | Activity Enhancing Curcumin Compositions and Methods of Use |
CA3226825A1 (en) * | 2014-06-19 | 2015-12-23 | Quercis Pharma AG | Method for treating cancer with a combination of quercetin and a chemotherapy agent |
CN107812195B (zh) * | 2014-09-04 | 2021-04-20 | 连云港金康和信药业有限公司 | (6s)‐5‐甲基‐四氢叶酸钙盐的稳定药物组合物 |
US10052293B2 (en) * | 2016-08-31 | 2018-08-21 | Srikumar MISRA | Curcumin infused milk beverage and a process for the preparation thereof |
US10750758B2 (en) | 2016-08-31 | 2020-08-25 | Srikumar MISRA | Curcumin infused milk beverage and a process for the preparation thereof |
CN107050011A (zh) * | 2017-04-28 | 2017-08-18 | 灏ゅ己 | 染料木素在制备抗自身免疫性肝炎药物中的应用 |
RU2699932C1 (ru) * | 2018-11-14 | 2019-09-11 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Осетинская государственная медицинская академия" Министерства здравоохранения Российской Федерации | Способ прогнозирования риска развития рака печени у экспериментальных животных |
CN113164440A (zh) | 2018-11-30 | 2021-07-23 | 贝斯以色列女执事医疗中心有限公司 | 减少癌症患者的主要血栓事件的组合物和方法 |
CN114340609A (zh) * | 2019-08-06 | 2022-04-12 | 连云港金康和信药业有限公司 | 产生安全量的一氧化氮的药物组合物及其用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002542202A (ja) * | 1999-04-19 | 2002-12-10 | シェリング・コーポレーション | 抗酸化剤を伴ったリバビリンを含有するhcv組み合わせ治療薬 |
JP2006503896A (ja) * | 2002-10-23 | 2006-02-02 | クエルセジーン ホールディングス エルエルシー | 身体能力向上のための組成物 |
JP2009543883A (ja) * | 2006-07-17 | 2009-12-10 | クリスチャン ラインズ,トーマス | ケルセチン含有組成物 |
US20100010005A1 (en) * | 2008-07-09 | 2010-01-14 | Thomas Christian Lines | Renal Function with Quercetin-Containing Compositions |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6294350B1 (en) * | 1997-06-05 | 2001-09-25 | Dalhousie University | Methods for treating fibroproliferative diseases |
WO1999055326A1 (en) * | 1998-04-30 | 1999-11-04 | Vit-Immune, L.C. | Method of treatment of glutathione deficient mammals |
US20050245502A1 (en) * | 1999-08-23 | 2005-11-03 | Phoenix Biosciences | Treatments for viral infections |
WO2003030929A1 (en) * | 2001-10-05 | 2003-04-17 | Transition Therapeutics Inc. | Combination therapies using methyl donors or methyl donor enhancers and therapeutic agents for treatment of viral, proliferative and inflammatory diseases |
US7560123B2 (en) * | 2004-08-12 | 2009-07-14 | Everett Laboratories, Inc. | Compositions and methods for nutrition supplementation |
CN100361599C (zh) * | 2002-10-23 | 2008-01-16 | 克尔塞根控股有限公司 | 抗氧化组合物 |
EP1606285A4 (en) * | 2003-03-27 | 2009-03-18 | Lankenau Inst Medical Res | IDO INHIBITORS AND METHODS OF USE THEREOF |
WO2004112483A1 (en) * | 2003-06-13 | 2004-12-29 | Bui Can V | Nutraceutical for the prevention and treatment of cancers and diseases affecting the liver |
WO2007067957A1 (en) * | 2005-12-07 | 2007-06-14 | Cardax Pharmaceuticals, Inc. | Structural carotenoid analogs or derivatives for the modulation of systemic and/or target organ redox status |
US7745487B2 (en) * | 2006-07-17 | 2010-06-29 | Quercegen Pharma Llc | Method for enhancing physical performance or immune system recovery from intense physical excercise with quercetin-containing compositions |
US20100166796A1 (en) * | 2007-01-31 | 2010-07-01 | Robert Keller | Method of increasing cellular function and health of glutathione deficient animals |
-
2011
- 2011-11-23 US US13/303,467 patent/US20130129680A1/en not_active Abandoned
-
2012
- 2012-11-20 KR KR1020147016393A patent/KR20140102227A/ko not_active Application Discontinuation
- 2012-11-20 CA CA2856506A patent/CA2856506A1/en not_active Abandoned
- 2012-11-20 CN CN201280057722.XA patent/CN104487074A/zh active Pending
- 2012-11-20 RU RU2014125062/15A patent/RU2014125062A/ru not_active Application Discontinuation
- 2012-11-20 AU AU2012340840A patent/AU2012340840B2/en not_active Ceased
- 2012-11-20 JP JP2014543531A patent/JP2014533729A/ja active Pending
- 2012-11-20 EP EP12852154.9A patent/EP2782578A4/en not_active Withdrawn
- 2012-11-20 MX MX2014006244A patent/MX2014006244A/es unknown
- 2012-11-20 BR BR112014012610A patent/BR112014012610A2/pt not_active IP Right Cessation
- 2012-11-20 WO PCT/US2012/066027 patent/WO2013078184A2/en active Application Filing
-
2014
- 2014-05-23 IN IN999MUN2014 patent/IN2014MN00999A/en unknown
- 2014-06-19 ZA ZA2014/04494A patent/ZA201404494B/en unknown
-
2015
- 2015-09-17 HK HK15109096.7A patent/HK1208364A1/xx unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002542202A (ja) * | 1999-04-19 | 2002-12-10 | シェリング・コーポレーション | 抗酸化剤を伴ったリバビリンを含有するhcv組み合わせ治療薬 |
JP2006503896A (ja) * | 2002-10-23 | 2006-02-02 | クエルセジーン ホールディングス エルエルシー | 身体能力向上のための組成物 |
JP2009543883A (ja) * | 2006-07-17 | 2009-12-10 | クリスチャン ラインズ,トーマス | ケルセチン含有組成物 |
US20100010005A1 (en) * | 2008-07-09 | 2010-01-14 | Thomas Christian Lines | Renal Function with Quercetin-Containing Compositions |
Non-Patent Citations (2)
Title |
---|
JPN6016028726; Journal of Viral Hepatitis vol.19, 20110816, p.e81-e88 * |
JPN6016028728; Hepatology vol.50, 2009, p.1756-1764 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021524495A (ja) * | 2018-07-10 | 2021-09-13 | ヌチド リミテッド | 酸化的ストレスおよびミトコンドリアストレスから,細胞を保護する組成物 |
Also Published As
Publication number | Publication date |
---|---|
MX2014006244A (es) | 2015-03-03 |
IN2014MN00999A (ja) | 2015-04-24 |
CN104487074A (zh) | 2015-04-01 |
US20130129680A1 (en) | 2013-05-23 |
ZA201404494B (en) | 2016-01-27 |
EP2782578A4 (en) | 2016-01-13 |
HK1208364A1 (en) | 2016-03-04 |
AU2012340840B2 (en) | 2016-06-30 |
EP2782578A2 (en) | 2014-10-01 |
AU2012340840A1 (en) | 2014-06-12 |
WO2013078184A2 (en) | 2013-05-30 |
NZ625746A (en) | 2016-08-26 |
BR112014012610A2 (pt) | 2017-06-06 |
KR20140102227A (ko) | 2014-08-21 |
RU2014125062A (ru) | 2015-12-27 |
CA2856506A1 (en) | 2013-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2012340840B2 (en) | Method for treating hepatitis C virus infection using quercetin-containing compositions | |
EP2040708B1 (en) | Quercetin-containing compositions | |
US7745487B2 (en) | Method for enhancing physical performance or immune system recovery from intense physical excercise with quercetin-containing compositions | |
US8318225B2 (en) | Composition for enhancing physical performance | |
ES2362649T3 (es) | Composición para mejorar el rendimiento físico. | |
JP2011157366A (ja) | 身体能力向上のための組成物 | |
US20220000835A1 (en) | Method for treating cancer with a combination of quercetin and a chemotherapy agent | |
EP2310007B1 (en) | Improving renal function with quercetin-containing compositions | |
CN102552908B (zh) | 含青蒿素及青蒿素类衍生物和Bcl-2抑制剂的药物组合物及其应用 | |
US20220096432A1 (en) | Method for treating zika virus infection with quercetin-containing compositions | |
NZ625746B2 (en) | Method for treating hepatitis c virus infection using quercetin-containing compositions | |
JPWO2011034006A1 (ja) | 血液中の尿酸値を低下させるための組成物 | |
Freye et al. | Changes within the Electroencephalogram and Increase in Mental Concentration are related to Differences in Solubulisation and Composition of Different Q10-Formulations | |
Freye et al. | Different Q10-Formulations Result in an Increase in the Fast Beta-Domain of the EEG | |
TW202312998A (zh) | 用於抑制或改善社會性健康度降低之組成物 | |
CA2894914A1 (en) | Formulations for preventing and treating decreasing platelet cell counts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140725 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151119 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160729 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160802 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161031 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20161213 |